Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01743651
• Other study ID #: OS440-3002
• Status: Completed
• Phase: Phase 3
• Start date: November 2012
• Est. completion date: April 2014

Study information

• Verified date: May 2014
• Source: RVL Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity.

Eligible subjects will be removed from anti-spasticity medications for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks.

Description:

This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity.

Eligible subjects will be removed from anti-spasticity medications for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks with the final study visit occurring at 19 weeks from start of achieving the target dose or 22 weeks from the Study Visit 1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 353
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients (male or female) 18 to 65 years of age, inclusive, at the time of dosing

• Have an established diagnosis (per McDonald Criteria) of Multiple Sclerosis (either relapsing remitting or secondary progressive course), that manifests spasticity for at least 6 months

• Spasticity due to MS as shown by a TNmAS score equal or greater than six (=6) in the most affected limb.

• EDSS equal or greater than 3.0

• If receiving disease-modifying medications, these must have been at a stable dose for at least three (3) months prior to screening, and the subject must be willing to maintain this treatment for the duration of the study

• Stable regimen for at least thirty (30) days prior to study entry for all medications and non-pharmacological therapies that are intended to alleviate spasticity

• Absence of infections, peripheral vascular disease, painful contractures, advanced arthritis, or other conditions that hinder evaluation of joint movement

• Have a creatinine clearance, as calculated by Glomerular Filtration Rate using the Modification of Diet in Renal Disease (MDRD) Study equation, greater than 60mL/min.

• Use of a medically highly effective of birth control during the study and for ninety (90) days thereafter for women of child-bearing potential (including female subjects and female partners of non-sterile male subjects)

• Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study

Exclusion Criteria:

• Any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity

• Inability to rate their level of spasticity or distinguish it from other MS symptoms

• Acute MS exacerbation requiring treatment within twelve (12) weeks of screening

• Use of intravenous methylprednisolone within the twelve (12) weeks before visit 1

• Concomitant use of medications that would potentially interfere with the actions of the study medication or outcome variables

• Use of botulinum toxin A or B within six (6) months of visit 1

• History of allergy to baclofen or any inactive component of test or reference formulation

• Pregnancy, lactation or planned pregnancy during the course of the study and for three (3) months thereafter.

• History of unstable psychiatric disease, or current signs and symptoms of significant medical disorders such as severe, progressive, or uncontrolled pulmonary, cardiac, gastrointestinal, hepatic, renal, genitourinary, hematological, endocrine, immunologic, or neurological disease

• History of seizures

• Current significant cognitive deficit, severe or untreated anxiety, severe or untreated depression

• Subjects with abnormal micturition that requires indwelling or intermittent catheterization or with lower urinary tract symptoms (LUTS) that result in a score greater than twenty-six (>26) in the Baseline USP© questionnaire

• Current malignancy or history of malignancy that has not been in remission for more than five (5) years, except effectively treated basal cell skin carcinoma

• Any other significant disease, disorder or significant laboratory finding which, in the opinion of the investigator, put the subject at risk because of participation, influence the result of the study, or affect the subject's ability to participate

• Planned elective surgery or other procedures requiring general anesthesia during the study

• Subject who is inappropriate for placebo medication in the judgment of the Investigator

• History of substance abuse within the past twelve (12) months

• Current chronic use of long acting opioids or round the clock use of short acting opioids for the treatment of pain

• Participation in another research study within thirty (30) days of Screening

• Patients who are uncooperative or unwilling to sign consent form

Related Conditions & MeSH terms

• Multiple Sclerosis
• Muscle Spasticity
• Sclerosis
• Spasticity

Intervention

Drug:
• arbaclofen
40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
• baclofen
80 mg/day as 20 mg baclofen administered orally 4 times per day
• Placebo
arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day

Locations

Country	Name	City	State
Russian Federation	Osmotica Site-511	Krasnoyarsk
Russian Federation	Osmotica Study Site-508	Krasnoyarsk
Russian Federation	Osmotica Study Site-510	Krasnoyarsk
Russian Federation	Osmotica Study Site-501	Moscow
Russian Federation	Osmotica Study Site-502	Moscow
Russian Federation	Osmotica Study Site-509	Pyatigorsk	Stavropol Krai
Russian Federation	Osmotica Study Site-506	Sestroretsk
Russian Federation	Osmotica Study Site-507	St Petersburg
Russian Federation	Osmotica Study Site-503	St. Petersburg
Russian Federation	Osmotica Study Site-505	St. Petersburg
Russian Federation	Osmotica Study Site-510	Tonnel'nyy	Stavropol Krai
Ukraine	Osmotica Study Site 614	Chernigov
Ukraine	Osmotica Study Site-602	Dnipropetrovsk
Ukraine	Osmotica Study Site-603	Dnipropetrovsk
Ukraine	Osmotica Study Site-609	Dnipropetrovsk
Ukraine	Osmotica Study Site-611	Donetsk
Ukraine	Osmotica Study Site-613	Ivano-Frankivsk
Ukraine	Osmotica Site-605	Kharkov
Ukraine	Osmotica Study Site-604	Kharkov
Ukraine	Osmotica Study Site-610	Kharkov
Ukraine	Osmotica Study Site-606	Lviv
Ukraine	Osmotica Study Site-608	Odessa
Ukraine	Osmotica Study Site-615	Uzhgorod
United States	Osmotica Study Site-101	Ann Arbor	Michigan
United States	Osmotica Study Site-123	Aurora	Colorado
United States	Osmotica Study Site-124	Baltimore	Maryland
United States	Osmotica Study Site-110	Bradenton	Florida
United States	Osmotica Study Site-106	Charlotte	North Carolina
United States	Osmotica Study Site-131	Cincinnati	Ohio
United States	Osmotica Study Site-138	Cullman	Alabama
United States	Osmotica Study Site-108	Fort Wayne	Indiana
United States	Osmotica Study Site-115	Johnson City	New York
United States	Osmotica Study Site-116	Lenexa	Kansas
United States	Osmotica Site-143	Long Beach	California
United States	Osmotica Study Site-142	Maitland	Florida
United States	Osmotica Study Site-113	New York	New York
United States	Osmotica Study Site-125	New York	New York
United States	Osmotica Study Site-141	New York	New York
United States	Osmotica Study Site-126	Northbrook	Illinois
United States	Osmotica Study Site-119	Ormond Beach	Florida
United States	Osmotica Study Site-127	Pittsburgh	Pennsylvania
United States	Osmotica Study Site-120	Pompano Beach	Florida
United States	Osmotica Study Site-133	Salt Lake City	Utah
United States	Osmotica Study Site-112	San Antonio	Texas
United States	Osmotica Study Site-129	Seattle	Washington
United States	Osmotica Study Site-136	Springfield	Massachusetts
United States	Osmotica SIte-144	Tacoma	Washington
United States	Osmotica Study Site-109	Tampa	Florida

Sponsors (2)

Lead Sponsor	Collaborator
RVL Pharmaceuticals, Inc.	Osmotica Pharmaceutical US LLC

Countries where clinical trial is conducted

United States,  Russian Federation,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS) in the most affected limb.	Change from baseline through end of treatment in the pre-dose, morning TNmAS of the most affected limb. The most affected limb is determined at baseline using the sum of scores for three major motor groups. High scores indicate more severe spasticity.	Change in baseline from Visit 1 through Visit 9 (120 days) or end of treatment
Primary	Clinical Global Impression of Change (CGIC) through end of treatment	The CGIC is a global rating scale that captures the investigator's assessment of the subject's change in overall functional performance since starting the study. Scores range from -3 (significant worsening) to +3 (significant improvement.	Visit 9 (120 days) or end of study
Secondary	Changes in the Multiple Sclerosis Spasticity Scale (MSSS-88)	This MSSS-88 is a self-administered questionnaire for the subject to assess overall functional performance and sense of impairment with respect to the level of spasticity.	Baseline through Visit 9 (120 days)
Secondary	Changes in the TNmAS for the most affected limb	The modified Ashworth Scale is a six (6)-point rating scale that measures abnormality in tone or the resistance to passive movements. Measurements are made in three muscle groups of each limb. The most affect limb is determined at baseline, based on the sum of scores from each limb. Higher scores indicate more severe spasticity.	From baseline to visits 4 (22 days), 5 (36 days), 6 (50 days), 7 (71 days), and 9 (120 days)
Secondary	Changes in the TNmAS for the sum of all limbs	The sums of scores from all limbs are compared to the baseline sum. Higher scores indicate more severe spasticity.	Baseline to visits 4 (22 days), 5 (36 days), 6 (50 days), 7 (71 days), and 9 (120 days)
Secondary	Changes in Expanded Disability Status Score (EDSS)	The EDSS is based on an examination by a neurologist with a scale that ranges from zero (0) to ten (10) in half point (0.5) unit increments. Higher scores represent higher levels of disability.	Baseline to Visit 9 (120 Days)
Secondary	Changes in the Lower Extremity Manual Muscle Testing (LEMMT) Scale	The LEMMT Scale is an evaluation of the function and strength of individual muscles and muscle groups based on effective performance of limb movement in relation to the forces of gravity and manual resistance. Maximum muscular strength is the maximum amount of tension or force that a muscle or muscle group can voluntarily exert in one maximal effort. Scores for each muscle or muscle group range from 0 (no detectable activity) to 5 (normal activity).	Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary	Changes in Epworth Sleepiness Scale (ESS)	The ESS is used to determine the level of daytime sleepiness. The questionnaire asks the subject to rate his or her probability of falling asleep on a scale of increasing probability from 0 to 3 in eight different situations.	Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary	Changes in the subject-recorded mean daily Drowsiness Numerical Rating Scale (DNRS)score for the day prior to each visit	Drowsiness will be reported by the subject using a numerical rating scale with a range of zero (0; no drowsiness) to ten (10; worst possible drowsiness). Scores will be recorded every 3 hours during the day before each designated visit.	Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary	Changes in the Urinary Symptom Profile (USP) Scale	The USP is a Health-Related Quality of Life questionnaire composed of 13 items assessing urinary symptoms in adults with stress, urge, overactive bladder, or urinary obstructive symptoms.	Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days)
Secondary	Clinical Global Impression of Change (CGIC)	The CGIC scores will be recorded at the designated intervals prior to Visit 9 (end of study)	Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days)